ClinicalTrials.gg
Active, not recruitingNCT05252429Updated Sep 12, 2025

Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma

A Phase 2 interventional study of Docetaxel and Pembrolizumab in Effect of Drug, sponsored by Hokkaido University Hospital. Active, not recruiting at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Hokkaido University Hospital · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies testing docetaxel in Head and Neck Neoplasms — 3 open to participants now, 6 under way, none of them phase 3. Docetaxel · Head and Neck Neoplasms.

Planned enrollment
40th of 64
27 · median 34
Started
2022
the only one that year
Phase 2
43 of 68
3 open now
Registered
66th of 68
by date

Among the 68 studies testing docetaxel in Head and Neck Neoplasms, this one is the 40th largest by planned enrollment of the 64 interventional ones that give a count, is the only one that started in 2022, is one of 43 in phase 2, and was the 66th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

3 of the 68 studies testing docetaxel in Head and Neck Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies testing docetaxel in Head and Neck Neoplasms, or all of them as a file.
02

Study summary

Pembrolizumab monotherapy and platinum-based chemotherapy in the combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have been widely used in daily clinical practice based on the KEYNOTE-048 study. On the other hand, docetaxel is a commonly used antimitotic agent in cancer therapy and might have potent antitumor effect by the immune response. A combination therapy of docetaxel and pembrolizumab might be a promising treatment for R/M HNSCC. The KEYNOTE-048 study showed that pembrolizumab plus platinum and 5-fluorouracil is a tolerable treatment for R/M HNSCC. The main grade 3/4 adverse event of platinum and 5-fluorouracil was myelosuppression such as neutropenia similar to docetaxel in some studies for R/M HNSCC. The safety profile of platinum and 5-fluorouracil is not much different from docetaxel. Therefore, docetaxel/pembrolizumab combination treatment might also be tolerable. The hypothesis of this study is that a combination therapy of docetaxel and pembrolizumab will provide benefit for patients with R/M HNSCC.

03

Conditions studied

  • Effect of Drug

Keywords

  • head and neck cancer, docetaxel, pembrolizumab
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have or cytologically-confirmed R/M HNSCC that is considered incurable by local therapies.

    Subjects should not have had prior systemic therapy administered in the recurrent or setting. Systemic therapy which was completed more than 6 months prior to signing consent if given as part of multimodal treatment for locally advanced disease is allowed.

    The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx. Subjects may not have a primary tumor site of nasopharynx (any histology).

  2. Be willing and able to provide written for the trial.
  3. Have results from testing of status.
  4. Be ≥ 20 years of age on day of signing informed consent.
  5. Have based on 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  6. Have a performance status of 0 or 1 on the ECO G Performance Scale.
  7. Have adequate organ function.
  8. Have results from testing of HPV status for oropharyngeal cancer.
  9. Female subjects of should have a negative blood pregnancy test within 72 hours prior to receiving the first dose of study medication.
  10. Female subjects of childbearing potential should be willing to use 2 methods of or be surgically sterile or abstain from heterosexual activity for the course of the study through 180 days after the last dose of study medication.
  11. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 180 days after the last dose of study therapy.

Exclusion criteria

Exclusion Criteria:

  1. Has disease that is suitable for local therapy administered with curative intent.
  2. Has a of less than 3 months and/ or has rapidly progressing disease in the opinion of the treating investigator.
  3. Has received prior systemic anti-cancer therapy including radiation therapy, other non-systemic therapy or agents within 4 weeks prior to the first dose of trial treatment.
  4. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy, or used an investigational device, any of which occurred within 4 weeks of the first dose of treatment.
  5. Has a diagnosis of immunodeficiency or is receiving systemic therapy (using prednisolone ≥ 10mg per day) or any other form of therapy within 7 days prior to the first dos e of trial treatment.
  6. Has a diagnosed and/or treated additional within 2 years prior to randomization with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, curatively resected esophageal cancer, curatively resected in situ cervical cancer, and curatively resected in situ cancer.
  7. Has known active central nervous system (CNS) and/or carcinomatous meningitis.
  8. Active disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
  9. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis. Pneumonitis include active radiation pneumonitis.
  10. Has an active infection requiring systemic therapy.
  11. Has received prior therapy with an , a nti-PD-L1, or anti-CTLA-4 agent.
  12. Has a known history of (HIV) (HIV 1/2 antibodies). Has known active (e.g., HBsAg reactive) or (e.g., HCV RNA is detected).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Docetaxel plus pembrolizumab

    Docetaxel 75mg/m2 plus pembrolizumab 200mg will be administered every 3 weeks intravenously for 6 cycles. Thereafter pembrolizumab 200mg every 3 weeks will be given as maintenance therapy until progression or up to 35 cycles.

    Drug: Docetaxel · Drug: Pembrolizumab

Interventions

  • Docetaxel 75mg/m2; q21

    Also known as: Taxotere

  • Pembrolizumab 200mg, q21

    Also known as: Keytruda

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR)

    Overall response rate is estimated per RECIST 1.1 by blinded independent central review (BICR).

    Time frame: 1 year

Secondary outcomes

  1. Overall survival (OS)

    For overall survival, the survival curve is estimated by the Kaplan-Meier method.

    Time frame: 1 year

  2. Progression-free survival (PFS)

    For progression-free survival, the survival curve is estimated by the Kaplan-Meier method.

    Time frame: 1 year

  3. Duration of response (DoR)

    For duration of response, the survival curve is estimated by the Kaplan-Meier method.

    Time frame: 1 year

  4. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Drug induced toxicities are assessed and graded according to Common Toxicity Criteria for Adverse Events (CTCAE) Version 5.0.

    Time frame: From treatment start date to 30 days after the final administration of the study drug

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in May 2025, 34 months.

Of 219 non-industry phase 2 interventional studies under Head and Neck Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 84. This study's 34 months is below that.

Counting every sponsor, half of 263 studies reached it within 51 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2022
First posted
Feb 23, 2022
StartActual
Jul 6, 2022
Primary completionActual
May 31, 2025
CompletionEst.
Nov 30, 2025
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05252429
Lead sponsor
Hokkaido University Hospital
Responsible party
Yasushi Shimizu (Clinical associate professor, Hokkaido University Hospital) — Principal investigator
First posted
Feb 23, 2022
Start date
Jul 6, 2022
Primary completion
May 31, 2025
Completion
Nov 30, 2025 (estimated)
Last update
Sep 12, 2025

Study contacts

Yasushi Shimizu
principal investigator · Hokkaido University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Pembrolizumab

Start the discussion